Newsroom | 19920 results

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (m...

SAN FRANCISCO--(BUSINESS WIRE)--The Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) today announced it has been awarded a $46 million grant from Aligning Research to Impact Autism (ARIA) to expand its landmark research into the molecular mechanisms underlying autism spectrum disorder (ASD). The funding directly builds on a study published today in Science (DOI: 10.1126/science.ady4523) in which UCSF scientists at QBI and the Department of Psychiatr...

WEST CHESTER, Ohio--(BUSINESS WIRE)--LetsGetChecked now offers the most comprehensive FDA-cleared at-home HPV screening tool available in the U.S....

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that management will participate in the following investor conferences: Cantor 2026 Global Healthcare Conference: Scholar Rock is scheduled to participate in a fireside chat at 8:00 a.m. ET on Wednesday, September 9, 20...

PHILADELPHIA--(BUSINESS WIRE)--iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors....

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST trial evaluating neoadjuvant botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, and balstilimab (BAL), Agenus’ anti-PD-1 antibody, in patients with resectable colon cancer. The manuscript, titled “Neoadjuvant botensilimab/balstilimab for localized mismatch r...

SEOUL, South Korea--(BUSINESS WIRE)--An AI biotech company Galux earns recognition on Forbes Asia’s 100 to Watch for its advances in AI protein design and growing network of partnerships...

CARLSBAD, Calif. & BILBAO, Spain--(BUSINESS WIRE)--Artis BioSolutions, a company founded to streamline the discovery, development, and production of genetic medicines, today announced the launch of its Genetic Medicines Center of Excellence in Bilbao, Spain. The new center expands the company's integrated development and manufacturing capabilities, strengthening its position as a leading technology innovator and manufacturer for next-generation genetic medicines. The center provides an end-to-e...